Landec Corporation reiterated consolidated earnings guidance for the fiscal year 2022. For the year, the company expects pro forma consolidated revenue from continuing operations to be in the range of $179 million to $185 million (+4% to +8%).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.83 USD | -2.18% | -2.67% | -5.82% |
Apr. 19 | Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report | MT |
Apr. 01 | Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.82% | 178M | |
+37.74% | 723B | |
+34.25% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+17.08% | 244B | |
+9.72% | 208B | |
-4.25% | 205B | |
+2.81% | 168B |
- Stock Market
- Equities
- LFCR Stock
- News Lifecore Biomedical, Inc.
- Landec Corporation Reiterates Consolidated Earnings Guidance for the Fiscal Year 2022